This project presents one application direction of the IARIP research architecture. The presented model is currently in the research and pilot validation phase. The timelines below outline the expected validation and development steps of the IARIP research architecture across different application domains. Following research validation, IARIP aims to initiate real-world projects together with industry and market partners based on the successfully validated models.

An integrated platform for bioinformatic profiling and plant-based bioactive development

Project Overview

The objective of the Complex Biotechnological Innovation Pilot is to establish an integrated biotechnology development model that combines bioinformatic analysis, plant-based bioactive research, and AI-supported decision support within a single, scalable framework.

The project is not a clinical or therapeutic system.
It is a research and innovation platform designed to:

• – structurally interpret individual biological patterns,
• – identify and prioritize development pathways,
• – and pre-validate bio-based solutions before further investment or clinical translation.

The pilot demonstrates a clear data → interpretation → development direction workflow in a controlled, low-risk setting.

Pilot Scope (0–24 months)

The initial phase focuses on a limited-scale yet complete system demonstration.

Pilot objectives:

• – development of a bioinformatic profiling model based on 5–10 key genes and core metabolic indicators,
• – selection of a defined lifestyle- or inflammation-related focus area,
• – targeted identification and preliminary validation of plant-derived bioactive compounds,
• – generation of integrated decision-support reports.

The pilot operates on fully anonymized, research-grade datasets and does not require clinical intervention or therapeutic application.

Technological and Development Structure

The project is built on three tightly integrated pillars:

1. Bioinformatic Profiling

• – structured analysis of genetic and metabolic data,
• – identification of individual biological patterns and directional risks,
• – creation of dynamic, comparable biological profiles.

2. Plant-Based Bioactive Development

• – targeted compound selection based on literature and database analysis,
• – preliminary assessment of mechanisms and synergistic interactions,
• – laboratory-level bioactivity testing (non-clinical).

3. AI-Supported Integration and Decision Support

• – integration of bioinformatic and bioactive datasets,
• – prioritization of development pathways,
• – generation of structured reports for researchers and developers.

The emphasis is not automated decision-making, but interpretable, traceable development guidance.

Expected Pilot Outcomes

The project delivers concrete, measurable results:

• – a functional integrated biotechnological pilot model,
• – validated methodologies for bioinformatic profiling and compound selection,
• – documented development workflows,
• – a demonstrator suitable for institutional and industrial collaboration,
• – a foundation for future personalized health-technology initiatives.

The pilot is intended for technological and methodological validation, not immediate market launch.

Why This Project Is Pilot-Ready and Strategically Important

• – modular architecture enabling controlled risk,
• – no clinical or medical regulatory requirements,
• – strong compatibility with academic and research institutions,
• – direct integration with existing Bio-Nano and AI projects.

This initiative functions as a connecting core between standalone bioinformatics, nutraceutical, and future health-ecosystem developments.

Alignment with the AVA Development Framework

Within this pilot, AVA operates as an integrative intelligence layer, supporting:

• – connection of heterogeneous biological data layers,
• – recognition of patterns and development potential,
• – prioritization of research and innovation pathways.

The Complex Biotechnological Innovation Pilot thus serves not as an isolated project, but as the organizational nucleus of the Bio–Nano portfolio—providing a stable base for larger-scale systems such as AVA LIFE and beyond.